INDRAMEDCO360.50

Indraprastha Medical Corporation Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersARTEMISMEDSHALBYGKSLGPTHEALTHLOTUSEYEDRAGARWQKMCSHILKOVAIMcap ₹3,305 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations317.0306.5314.7347.9349.8324.9333.8365.1381.0371.6364.8406.2
Other Income4.24.34.95.16.15.16.46.97.47.27.38.4
Total Income321.2310.7319.6353.0355.9330.1340.1372.0388.4378.8372.1414.6
Expenses
+ Cost of Materials Consumed57.150.555.558.956.256.259.162.865.563.864.370.1
+ Employee Benefit Expense67.166.564.866.671.672.266.765.073.674.974.273.0
+ Finance Costs0.90.91.61.61.61.61.51.61.51.51.51.7
+ Depreciation & Amortisation10.010.010.211.011.211.210.910.210.911.311.311.8
+ Other Expenses142.5142.2146.0155.2158.3144.4146.6164.1170.7171.0165.8183.3
Total Expenses277.5270.1278.1293.4298.9285.5284.8303.7322.1322.4317.1339.8
EBITDA50.447.348.467.163.652.261.373.271.362.060.579.8
EBIT40.337.338.256.152.541.050.463.060.550.749.268.1
Profit
PBT before Exceptional Items43.740.741.659.656.944.555.368.366.356.455.074.8
Pretax Income43.740.741.659.656.944.555.368.366.356.455.074.8
+ Current Tax11.311.79.215.215.211.917.117.416.412.611.519.7
+ Deferred Tax-0.5-0.51.2-0.4-0.7-0.2-2.8-0.60.52.81.8-0.7
Tax Expense10.811.210.414.814.511.714.316.916.915.413.319.0
Net Income32.929.431.244.842.432.841.051.549.541.041.755.9
+ Net Income — Continuing Ops32.929.431.244.842.432.841.051.549.541.041.755.9
+ Other Comprehensive Income-0.21.51.02.0-1.2-0.1-1.54.5-2.50.5-1.12.3
Total Comprehensive Income32.630.932.146.841.232.739.555.947.041.540.658.1
Per Share
Basic EPS3.583.213.404.884.633.584.475.615.404.474.556.09
Diluted EPS3.583.213.404.884.633.584.475.615.404.474.550.00
Other Comprehensive Income — detail
+ Other Comprehensive Income-1.54.5-2.50.5-1.12.3
+ Items NOT to be Reclassified to P&L-0.31.91.32.6-1.6-0.2-2.06.0-3.30.6-1.53.0
+ Tax on Items NOT to be Reclassified-0.51.5-0.80.2-0.40.8
+ Tax on Items NOT to be Reclassified — alt tag-0.10.50.30.7-0.4-0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations3.583.213.404.884.633.584.475.615.404.474.556.09
Diluted EPS — Continuing Operations3.583.213.404.884.633.584.475.615.404.474.550.00
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period78.084.581.2
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit259.9256.0259.2288.9293.6268.8274.6302.2315.6307.9300.5336.0
Gross Margin %81.9983.5382.3583.0683.9382.7182.2982.7982.8282.8482.3782.73
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)43.740.741.659.656.944.555.368.366.356.455.074.8
Net Income Adj (tax-effected)32.929.431.244.842.432.841.051.549.541.041.755.9
EPS Adj3.583.213.404.884.633.584.475.615.404.474.556.09
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.00
Paid Up Equity Capital91.791.791.791.791.791.791.791.791.791.791.791.7
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.